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Neuromyelitis optica spectrum disorder (NMOSD) is a diverse condition which not 
only encompasses isolated longitudinally extensive transverse myelitis (LETM) and 
optic neuritis but also includes area postrema syndrome, acute brainstem syndrome, 
symptomatic narcolepsy or acute diencephalic clinical syndrome, and symptomatic 
cerebral syndrome. Imaging may reveal periependymal lesions surrounding the ventric-
ular system or involvement of corticospinal tracts, area postrema, diencephalon, and 
corpus callosum. Rarely, there may be hemispheric tumefactive lesions that enhance in a 
“Cloud-like” fashion on gadolinium injection unlike in tumefactive multiple sclerosis where 
there is incomplete ring enhancement. Here, we present a case of aquaporin-4 positive 
relapsing NMOSD who presented to us with recurrent episodes of paraparesis with 
LETM and tumefactive lesions of brain on imaging, which enhanced in an incomplete 
ring like pattern resembling multiple sclerosis.
Keywords: neuromyelitis optica spectrum disorder, longitudinally extensive transverse myelitis, aquaporin-4, 
tumefactive multiple sclerosis, therapeutic plasma exchange
BaCKGRoUND
Neuromyelitis optica (NMO) is an inflammatory CNS disorder that was initially thought to be a vari-
ant of multiple sclerosis (MS), but with the discovery of serum antibodies (Ab) against aquaporin-4 
(AQP4), it is now considered a distinct entity from MS. Traditionally, NMO was considered a mono-
phasic disorder that consisted of simultaneous bilateral optic neuritis and transverse myelitis, but 
relapsing cases have been clearly described (1). Magnetic resonance imaging (MRI) reveals involve-
ment of more than three vertebral segments, which is synonymous with longitudinally extensive 
transverse myelitis (LETM) (1). Nevertheless, some cases may be difficult to diagnose with certainty, 
especially where there are overlapping features of both NMO and MS and those who test negative for 
AQP4-Ab. Since NMO is primarily an astrocytopathy and MS is a demyelinating disorder, treatment 
of these disorders is quite distinct and they need to be differentiated so that appropriate treatment is 
started as early as possible to reduce the significant morbidity associated with these disorders. Hence, 
knowledge of lesion location and characterization of these lesions on neuroimaging is of utmost 
importance before treatment can be initiated (1).
FIGURe 2 | MRI screening of brain showing single focal  
well-circumscribed hyperintense lesion (arrow) in t2 sequence at 
right subcortical frontal region (at gray white interface).
FIGURe 1 | MRI of cervical spine done prior to admission showing long segment centrally located lesions in form of t2 hyperintensity in cervical 
cord (double arrow) [saggital (a), axial (D)] and dorsal cord (single arrow) [saggital (B,C), axial (e)].
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Case RepoRt
A 21-year-old girl, while attending college, was referred to our 
outpatient department with a 12-day history of gradual onset of 
quadriparesis. Weakness was present both proximally and distally, 
was initially asymmetric to start with but reached its nadir and 
became almost symmetric within 2 days. Along with her weak-
ness she also experienced decreased sensation up to her lower 
chest and developed incontinence of urine. There was no history 
of any convulsions, loss of consciousness/altered sensorium, 
decreased vision, diplopia, facial weakness, or dysphagia. After 
review of the initial MRI and cerebrospinal fluid (CSF) profile, 
the patient had been prescribed anti-tubercular drugs along with 
steroids 1 week earlier by a local practitioner and associated with 
mild improvement in her symptoms.
On examination, she had a temperature of 37.2°C; no palpable 
lymph nodes were detected. The remainder of her general exami-
nation was unremarkable. On neurological examination, she was 
conscious, well-oriented but apprehensive. Tone was increased 
in both lower limbs; however, it was normal in the upper limbs. 
Strength was decreased in all four limbs (2/5 in both upper 
limbs and 1/5 in lower limbs), and muscle stretch reflexes were 
increased with Babinski sign bilaterally. On sensory examination, 
superficial and deep sensation to all modalities was diminished 
below the C7 dermatome.
Routine blood investigations, including complete blood count, 
erythrocyte sedimentation rate, blood sugar (BS), serum electro-
lytes, and liver and kidney function tests were normal. Serologies 
for human immunodeficiency virus, hepatitis C virus, hepatitis B 
surface antigen, and tuberculosis skin test were negative. Collagen 
vascular disease work up was also non-contributory. Chest X-ray 
and ultrasonography of the abdomen were also normal. MRI of 
the cervical spine, done prior to admission, had revealed long 
segment lesions with T2 hyperintensity in cervical and dorsal 
cord favoring demyelination (Figure  1). CSF study done prior 
to presentation at our hospital had shown 350 cells out of which 
62% were neutrophils and 38% were mononuclear cells, protein 
was 180 mg/dL and sugar was 50 mg/dL (BS: 82).
On presentation at our center, we performed a MRI of the 
brain that revealed a single well-circumscribed T2 hyperintense 
lesion in the right subcortical frontal region (at gray white inter-
face) (Figure  2) without any diffusion restriction or contrast 
FIGURe 3 | Repeat MRI brain showing bilateral frontal–parietal 
hyperintensities on t2 sequence (single arrow) with central 
hypointensity on FLaIR (double arrow) (a,B). On contrast injection 
incomplete ring enhancement was seen (triple arrow) (C,D).
FIGURe 4 | Cervical MRI showing long segment t2 hyperintensity 
(arrow) (a) patchily enhancing in cervical cord (double arrow) and 
dorsal cord (B).
3
Roy et al. Neuromyelitis Optica with Tumefactive Demyelination
Frontiers in Neurology | www.frontiersin.org May 2016 | Volume 7 | Article 73
enhancement. Accordingly, we repeated the CSF study in view 
of these lesions that showed 300 cells out of which 58% were 
neutrophils and 42% were mononuclear cells; however, there 
were no red blood cells. Protein was 203  mg/dL, sugar was 
60 mg/dL (BS: 82), tuberculosis polymerase chain reaction was 
negative, and adenosine deaminase came out to be 3.2  U/L. 
Furthermore, oligoclonal band (OCB) was positive in the CSF. 
In view of the longitudinally extensive myelitis and a high CSF 
count, AQP4-Ab was also ordered. Although visual-evoked 
potentials (VEP) test was normal bilaterally, somatosensory 
evoked potentials (SSEPs) were suggestive of prolonged latency 
of N13 and N17 waveforms.
We made the provisional diagnosis of NMO spectrum disor-
der (NMOSD) in light of overall picture. She received a 5-day 
course of 500 mg daily intravenous methyl-prednisolone (IVMP) 
followed by oral prednisolone (OPN) at a dose of 1 mg/kg/day 
(60  mg). Significant improvement in power was noted (4/5 in 
upper limbs and 2/5 in lower limbs) at the seventh day from 
initiation of therapy. Meanwhile AQP4-Ab (done by indirect 
immunofluorescence) was positive (1:500 titer), so azathioprine 
therapy was initiated at a dose of 50 mg daily and subsequently 
increased to 100 mg/day over the next 4 weeks with monitoring 
of blood counts and liver function tests. Meanwhile, OPN was 
continued at the same dose.
The patient’s neurological status remained unchanged over 
for next 5 weeks when she developed a left focal motor seizure, 
neck weakness, and bilateral facial and bulbar palsy along 
with increased weakness in all four limbs. A repeat MRI of the 
brain revealed bilateral frontal–parietal hyperintensities on T2 
sequence with central hypointensity on FLAIR (Figures 3A,B). 
Furthermore, on contrast injection incomplete ring enhance-
ment was noted (Figures 3C,D). Cervical MRI showed patchy 
enhancing long TR hyperintensities in cervical and dorsal cord 
favoring demyelination (Figures 4A,B). We decided to treat the 
patient with five cycles of therapeutic plasma exchange (TPE) 
along with IVMP. On the fourth day of TPE, she again started 
recovering with regard to extremity strength and with signifi-
cant improvement in facial and bulbar weakness as well. She was 
discharged on azathioprine and continued physiotherapy at 
home. At her 4 months follow–up, she was ambulatory, had re-
joined her college, and was doing fine otherwise. Subsequently, 
OPN was tapered off and azathioprine maintained at a dose of 
125 mg/day.
DIsCUssIoN
Recently, a revised diagnostic criterion for NMOSD has been 
proposed by the International Panel for NMO Diagnosis that has 
stratified this disorder further by serologic testing (NMOSD with 
or without AQP4-IgG positivity). The “core clinical characteris-
tics” have been described as clinical syndromes or MRI findings 
related to optic nerve, spinal cord, area postrema, other brainstem, 
diencephalic, or cerebral presentations, and only one out of these 
six “core clinical characteristics” is required for the diagnosis of 
NMOSD in patients with AQP4-IgG positivity. Patients who are 
AQP4-IgG negative must experience two or more different core 
clinical characteristics either in a single clinical attack or multiple 
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attacks out of which one of the clinical events must be one of 
the three most common clinical characteristics of NMOSD: optic 
neuritis, LETM MRI lesion, or an area postrema clinical syn-
drome (2). Accordingly, we had diagnosed this patient as having 
AQP4-IgG positive NMOSD after the first attack.
In NMOSD, LETM (more than or equal to three vertebral 
segment of the spinal cord, mainly involving central/gray matter, 
appearing as a T1 hypointensity) and optic nerve involvement 
in the form of long-length/posterior-chiasmal lesions is charac-
teristic. In brain, there are periependymal lesions surrounding 
the ventricular system (wide-based along the ependymal lin-
ing), along with lesions involving corticospinal tracts. Rarely, 
there may be hemispheric tumefactive lesions that have faint or 
“Cloud-like” enhancement on MRI because of the preservation 
of integrity of blood–brain barrier (3). Cheng et al. studied the 
clinical and radiographic features of NMO patients with extensive 
brain lesions (EBLs) in China. They included 16 NMO patients 
with EBLs out of which 4 had tumefactive-like lesions on MRI of 
the brain. Contrast enhancement was absent or faint in three and 
open-ring in one among the patients who had tumefactive-like 
lesions (4). By contrast, patients with MS may also have large 
demyelinating lesions on MRI, but these lesions characteristi-
cally demonstrate incomplete or near complete (ovoid) ring 
enhancement (5, 6). This presentation of MS is called “tumefac-
tive multiple sclerosis (TMS)” in which a solitary intracranial 
lesion larger than 2.0 cm in diameter is a classical MRI finding, 
although multiple lesions have also been reported creating a 
diagnostic puzzle for both clinicians and radiologists. TMS usu-
ally carries a benign prognosis, so distinguishing its lesions from 
infection, abscess, and especially glioma is of utmost importance 
in avoiding unnecessary medical or surgical interventions (7). In 
our case, the patient’s MRI had LETM with bilateral tumefactive 
lesions of the brain with incomplete ring-like enhancement of 
the lesions that have been rarely reported in association with 
NMOSD.
Thus, without the identification of AQP4-Ab positivity, this 
could have posed a diagnostic dilemma and the patient could have 
been misdiagnosed as TMS. Furthermore, OCB were positive in 
the CSF and while the absence of CSF OCBs has been considered 
as a supportive evidence for NMOSD, they may be transiently 
detectable at the time of an attack (2). Additionally, there were 
some features classically described on MRI which favored a 
diagnosis of MS: MRI in patients with MS can demonstrate short, 
often multiple, peripheral, asymmetrical, posterior predominant 
lesions of spinal cord along with the classical “dawson fingers” 
(perpendicular to ventricles), U-fiber involvement, lesions of the 
inferior lateral ventricle, and temporal lobe of brain (3). These 
radiological features are clinically useful as treatment paradigms 
differ in cases of MS and NMOSD and an incorrect diagnosis poses 
a chance of significantly increased morbidity in these patients (2). 
This particularly applies to and concerns severe NMO relapses 
misdiagnosed as MS and treated with MS-modifying drugs. 
Exacerbations of NMO have been observed after treatment with 
interferon β, natalizumab, and fingolimod (3).
Our case had a relapsing type of presentation, and AQP4-
IgG was positive in her serum. Researchers have observed 
that patients with monophasic NMO are more commonly 
AQP4-IgG-seronegative as compared to those with established 
relapsing disease (8). Long-term outcome and disability of 
NMOSD depends on many factors, one of the most important 
being successful treatment of attacks. Hence, clinical attacks 
should be treated aggressively and an early and timely escala-
tion of therapy is recommended (9). Researchers have shown 
that pulse therapy with IVMP significantly improves clinical 
disability and augments the preservation of the retinal nerve 
fiber layer thickness (10, 11). When remission is absent or 
insufficient, five to seven cycles of TPE improves attack-related 
disability in both seropositive and seronegative patients with the 
possibility of the existence of other types of auto-Ab (12, 13). In 
our case, treatment was started at the earliest possible timeframe 
after presentation (even before AQP4-IgG result was available). 
Furthermore, in the second attack, we treated the patient with 
TPE and IVMP in combination and significant improvement 
was observed over the next few days. This is in contrast with the 
observations of previous researchers that have shown that pres-
ence of EBLs in NMO may portend a worse long-term prognosis 
(4). To summarize, patients who have EBLs may be candidates 
for aggressive therapy, which may change the ultimate outcome 
in these patients.
CoNCLUsIoN
Neuromyelitis optica spectrum disorder should be diagnosed 
promptly so that appropriate treatment is started as early as 
possible to reduce the significant morbidity associated with this 
disease. Therefore, knowledge of typical and atypical lesions on 
neuroimaging is of utmost importance when treating these disor-
ders. Although, tumefaction with incomplete ring enhancement 
is more commonly observed in MS, it can occur in this disorder 
and its presence is consistent with NMOSD, especially if other 
clinical, laboratory, and imaging findings support this diagnosis. 
Further studies may be required to know the exact incidence, 
cause, and associations of such presentation on imaging.
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